Previous studies have found that ILF3 was dysregulated in breast tumor, hepatocellular carcinoma, non-small cell lung carcinoma and ovarian cancer [17–20], indicating its potential functions in oncogenesis. Here, ILF3 is linked to breast neoplasm.